Search Results - G. Merlini
- Showing 1 - 5 results of 5
-
1
-
2
P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK by E. Kastritis, M. C. Minnema, M. A. Dimopoulos, G. Merlini, F. Theodorakakou, D. Fotiou, A. Huart, K. Belhadj, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, G. Palladini
Published in HemaSphere (2022-06-01)Get full text
Article -
3
P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK by E. Kastritis, G. Palladini, M. A. Dimopoulos, A. Jaccard, G. Merlini, F. Theodorakakou, D. Fotiou, M. C. Minnema, A. Wechalekar, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, S. Schönland
Published in HemaSphere (2022-06-01)Get full text
Article -
4
P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES by M. Gertz, A. Cohen, R. Comenzo, E. Kastritis, H. Landau, E. Libby, M. Liedtke, V. Sanchorawala, S. Schönland, A. Wechalekar, Y. Ando, Y. Koh, J. Zonder, G. Palladini, C. Nie, C. Karp, Y. Jin, A. Conrad, G. Kinney, G. Merlini
Published in HemaSphere (2023-05-01)Get full text
Article -
5
P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE by A. Jaccard, F. Bridoux, W. Roeloffzen, M. C. Minnema, R. Bergantim, R. Hájek, C. João, M. T. Cibeira, G. Palladini, S. Schönland, G. Merlini, P. Milani, M. A. Dimopoulos, S. Ravichandran, U. Hegenbart, H. Agis, B. Gros, A. Asra, E. Dergarabetian, V. Magarotto, A. Leonidakis, G. Cheliotis, P. Sonneveld, A. Wechalekar, E. Kastritis
Published in HemaSphere (2022-06-01)Get full text
Article
